The National Agency for Food and Drug Administration and Control (NAFDAC), has vowed to allow the use of hydroxychloroquine for coronavirus clinical trials in Nigeria, despite its suspension by the World Health Organization (WHO)
The Agency’s Director-General, Professor Mojisola Adeyeye, said in a televised programme on TVC today, May 26, that NAFDAC “believes in hydroxychloroquine” and that it will continue clinical trials for hydroxychloroquine in Nigeria.
“There is data to prove that hydroxychloroquine worked for many covid-19 patients. Therefore, we would continue our own clinical trials in Nigeria.
“Hydroxychloroquine has been proved to work at a mild stage. So the potency depends on the severity of the disease in the patient’s body.
“If medical doctors, research scientists, pharmacists, herbal experts work together, we should conclude the clinical trial in three to four months. The narrative might change afterwards but for now, we believe in hydroxychloroquine.”
On why the virus has spread as much as it has in Europe and the US, Professor Adeyeye said: “it could be our weather or the vaccine we were given as kids but science would prove itself and we are working on gathering that data.”
Hydroxychloroquine is viewed as a possible treatment for the novel coronavirus and it gained further popularity when US President Donald Trump recently said he was taking the drug to keep coronavirus at bay.
Yesterday, May 25, the World Health Organization ordered for the discontinued clinical trials for hydroxychloroquine as a treatment for coronavirus.
